Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lipocine (LPCN) Short term Debt (2018 - 2022)

Lipocine (LPCN) has disclosed Short term Debt for 5 consecutive years, with $1.5 million as the latest value for Q1 2022.

  • For the quarter ending Q1 2022, Short term Debt fell 55.54% year-over-year to $1.5 million, compared with a TTM value of $1.5 million through Mar 2022, down 55.54%, and an annual FY2021 reading of $2.3 million, down 30.68% over the prior year.
  • Short term Debt was $1.5 million for Q1 2022 at Lipocine, down from $2.3 million in the prior quarter.
  • Across five years, Short term Debt topped out at $4.0 million in Q2 2021 and bottomed at $1.3 million in Q1 2018.
  • Average Short term Debt over 5 years is $2.7 million, with a median of $3.2 million recorded in 2020.
  • The sharpest move saw Short term Debt surged 148.66% in 2019, then crashed 55.54% in 2022.
  • Year by year, Short term Debt stood at $3.3 million in 2018, then changed by 0.0% to $3.3 million in 2019, then changed by 0.0% to $3.3 million in 2020, then plummeted by 30.68% to $2.3 million in 2021, then plummeted by 35.86% to $1.5 million in 2022.
  • Business Quant data shows Short term Debt for LPCN at $1.5 million in Q1 2022, $2.3 million in Q4 2021, and $3.1 million in Q3 2021.